SSSteven M. Shaw

Steven M. Shaw

*This is an algorithmically generated author record based on publicly available information.

Steven M. Shaw has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Second Line Options for Hyperlipidemia Management after Cardiac Transplantation

    by M.K.H. Shah, W.R. Critchley, N. Yonan, S.G. Williams, S.M. Shaw

    Summary: Despite widespread statin therapy, 91% of cardiac transplant patients have hyperlipidemia within 5 years from cardiac transplantation. The implications of this are profound, particularly given that coronary allograft vasculopathy is a leading cause of death. Unfortunately the solution is not easy, with problems of toleration at higher statin doses and a lack of good quality evidence for second line agents. We review the literature and discuss some of the key issues transplant physicians are faced with when considering alternatives to statin therapy.


  • Brain natriuretic peptide induces CD8+ T cell death via a caspase 3 associated pathway — Implications following heart transplantation

    by Steven M. Shaw, William R. Critchley, Christopher M. Puchalka, Simon G. Williams, Nizar Yonan, James E. Fildes


  • Open Access

    The Pathophysiology of Chronic Graft Failure in the Cardiac Transplant Patient

    by U. A. Khan, S. G. Williams, J. E. Fildes, S. M. Shaw


  • The Effect of Beta‐Blockers on the Adaptive Immune System in Chronic Heart Failure

    by Steven M. Shaw, Teresa Coppinger, Carolyn Waywell, Louise Dunne, Louise D. Archer, William R. Critchley, Nizar Yonan, James E. Fildes, Simon G. Williams

    It remains possible that the benefit from beta-blockers (BBs) in chronic heart failure (CHF) may not entirely be derived from a class-specific effect. Several experimental reports have alluded to the capability of immunomodulation by individual BBs. Given the increasingly recognized importance of the immune system in the pathogenesis of CHF, we studied the effects of BBs on the circulating immune system of these patients. Blood samples from CHF outpatients were prospectively analyzed using flow cytometry and gating software. Results were analyzed against comprehensive clinical details that were recorded during sample donation, including the type of BB administered. 273 blood samples were analyzed from 141 CHF patients, with an average ejection fraction of 31.9% and a mean age of 69.1 years. Patients taking carvedilol had a significantly lower expression of CD107a on cytotoxic T cells compared to bisoprolol (P= 0.001) and nebivolol (P= 0.008). They also had a significantly lower expression of HLA-DR on lymphocytes (P < 0.001 and P= 0.009 for bisoprolol and nebivolol, respectively). Cytotoxic T cells and lymphocytes expressing HLA-DR have been implicated in the pathogenesis of CHF. The fact that carvedilol, but not other commonly used beta-blockers, appears to modulate these important parameters, supports the concept that important differences exist between these agents, which may affect outcomes in CHF.


  • Open Access

    β-Blocker Use in Heart Failure Patients with Airways Disease

    by Steven M. Shaw, Jonathan Hasleton, Simon G. Williams


  • The Efficacy and Tolerability of Ezetimibe in Cardiac Transplant Recipients Taking Cyclosporin

    by Steven M. Shaw, Parminder Chaggar, James Ritchie, Mohammed K. H. Shah, Anna C. Baynes, Nicola O’nEill, James E. Fildes, Nizar Yonan, Simon G. Williams

    Despite statin treatment, hyperlipidemia remains problematic after cardiac transplantation and is associated with the development of cardiac allograft vasculopathy. The cholesterol absorption inhibitor ezetimibe may offer a viable option for add on therapy; however, questions have been raised regarding the safety of this during concomitant cyclosporin treatment. This is the first placebo controlled, randomized double blinded trial assessing the efficacy and tolerability of ezetimibe in cardiac transplant recipients receiving cyclosporin. Sixty-eight cardiac transplant patients were randomized to receive ezetimibe (10 mg) or matching placebo for 6 months in addition to usual treatments. Fasting blood tests were performed at regular time intervals during the study. Fifty-nine patients completed the study. At 6 months, ezetimibe had reduced total cholesterol by 18% (5.4+/-1.1 to 4.4+/-0.7 mmol/L, P<0.001), low-density lipoprotein cholesterol by 26% (3.0+/-1.0 to 2.1+/-0.7 mmol/L, P<0.001), and triglycerides by 13.5% (2.3+/-1.3 to 1.8+/-0.9 mmol/L, P=0.02). Tolerability was excellent with no patients experiencing predefined safety endpoints. An equal number of patients withdrew consent from each arm of the study because of perceived side effects. Specific analysis confirmed ezetimibe had no significant effect on cyclosporin levels. We conclude that ezetimibe is both efficacious and tolerable in cardiac transplant recipients taking cyclosporin. It can be safely considered as add on therapy in patients taking statins (or as monotherapy) to further reduce low-density lipoprotein levels, which may in turn reduce the risk of cardiac allograft vasculopathy.


  • BNP directly immunoregulates the innate immune system of cardiac transplant recipients in vitro

    by S.M. Shaw, J.E. Fildes, C.M. Puchałka, M. Basith, N. Yonan, S.G. Williams


  • Pleiotropic Effects and Cholesterol-Lowering Therapy

    by Steven M. Shaw, James E. Fildes, Nizar Yonan, Simon G. Williams

    HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase inhibitors, or ‘statins’, have revolutionized the management of patients with atherosclerotic vascular disease. Following 2 large acute coronary syndrome trials, additional clinical benefit outside their effect of low-density lipoprotein (LDL) lowering was proposed. This concept was introduced following the observation of cardiovascular event rate reduction, only weeks after initiation of treatment and supposedly before the effect of LDL lowering could have influenced atheroma volume burden. Furthermore, there has been a substantial compilation of experimental data demonstrating beneficial effects of statins on inflammation, thrombosis, platelet aggregation, immunomodulation and endothelial function. These are hypothesized to occur via the interruption of the mevalonate pathway. However, the absolute benefit of these non-lipid-lowering effects, often referred to as ‘pleiotropic effects’, has been challenged by meta-analysis data. Anti-inflammatory actions have also been proposed to occur by the process of LDL lowering alone rather than due to a unique property of statins. Furthermore, some experimental data reports have shown evidence of pleiotropic effects in non-statin lipid-modifying agents. In this review article, we consolidate what is known so far and critically analyse the literature in order to highlight the outstanding issues.


  • Does Brain Natriuretic Peptide Interact With the Immune System After Cardiac Transplantation?

    by Steven M. Shaw, James Fildes, Nizar Yonan, Simon G. Williams

    Brain natriuretic peptide (BNP) is a marker of diagnosis and prognosis in patients with chronic heart failure. Stored in ventricular myocytes, it is released during ventricular stretch and increased transmural pressure. However, BNP behaves unusually after cardiac transplantation, with a failure to return to normal levels. This raises a question over whether other processes are involved in both its production and secretion. Several studies suggest BNP levels are associated with allograft rejection and coronary graft vasculopathy. Both of these processes have a single denominator in common, the activated immune system. This overview considers further evidence suggesting that BNP interacts with the immune system after cardiac transplantation.